Detail akcie TScan Therapeut Rg online

Business Summary: TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Tscan Therapeutics Inc revenues increased from $2.2M to $7.8M. Net loss increased 16% to $106.8M. Revenues reflect Biotechnology & Medical Research segment increase from $1M to $2.5M. Higher net loss reflects Biotechnology & Medical Research segment loss increase of 14% to $37.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.84 to -$0.82.